Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | MGMT | P16455 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10379222 | 0.82 | PIK3CA (0.57) | PIK3CAMTORPIK3CGGBA1SMN1; SMN2 | |
| SCHEMBL5997136 | 0.77 | PIK3CA (0.40) | PIK3CAMTORPIK3CGGBA1SMN1; SMN2 | |
| SCHEMBL27617930 | 0.73 | PIK3CA (0.47) | PIK3CAMTORPIK3CGGBA1SMN1; SMN2 | |
| SCHEMBL5998120 | 0.72 | PIK3CA (0.46) | PIK3CAMTORPIK3CGGBA1SMN1; SMN2 | |
| SCHEMBL540122 | 0.71 | MGMT (0.58) | PIK3CAMTORPIK3CGDPP4ADORA1 | |
| SCHEMBL10380576 | 0.71 | PIK3CA (0.45) | PIK3CAMTORPIK3CGGBA1SMN1; SMN2 | |
| SCHEMBL6783434 | 0.70 | GRIA1 (0.59) | PIK3CAMTORPIK3CGSMN1; SMN2ADORA3 | |
| SCHEMBL19148655 | 0.69 | KDM4E (0.58) | SMN1; SMN2ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL356178 | 0.69 | DPP4 (0.61) | DPP4ADORA3 | |
| SCHEMBL11702923 | 0.68 | ADORA2A (0.51) | SMN1; SMN2ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009642-A1 | Methods for the synthesis of substituted purines | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2006-01-12 | — | — | US | disclosed |
| US-6949644-B2 | Methods for the synthesis of substituted purines | IRM LLC (BM) | 2005-09-27 | — | — | US | disclosed |
| EP-1529048-A4 | METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES | IRM LLC (BM) | 2005-09-14 | — | — | EP | disclosed |
| EP-1529048-A2 | METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES | IRM LLC (BM) | 2005-05-11 | — | — | EP | disclosed |
| US-20030171583-A1 | Methods for the synthesis of substituted purines | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2003-09-11 | — | — | US | disclosed |
| WO-2003031405-A2 | METHODS FOR THE SYNTHESIS OF SUBSTITUTED PURINES | IRM LLC (BM) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009642-A1 | Methods for the synthesis of substituted purines | PNP, ATIC, NUDT1 | PIK3CA 4389/4885MTOR 4488/4885PIK3CG 4495/4885 |
| US-20030171583-A1 | Methods for the synthesis of substituted purines | PNP, ATIC, NUDT1 | PIK3CA 4380/4885MTOR 4508/4885PIK3CG 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.